Molecule Information
General Information of the Molecule (ID: Mol01263)
| Name |
SLC25A25 antisense RNA 1 (SLC25A25-AS1)
,Homo sapiens
|
||||
|---|---|---|---|---|---|
| Synonyms |
SLC25A25-AS1
Click to Show/Hide
|
||||
| Molecule Type |
LncRNA
|
||||
| Gene Name |
NCRNA00030, SNHG2
|
||||
| Gene ID | |||||
| Location |
chr9:128108581-128118693[-]
|
||||
| Ensembl ID | |||||
| HGNC ID | |||||
| Click to Show/Hide the Complete Species Lineage | |||||
Type(s) of Resistant Mechanism of This Molecule
RTDM: Regulation by the Disease Microenvironment
Drug Resistance Data Categorized by Drug
Approved Drug(s)
2 drug(s) in total
Doxorubicin
| Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
|
Regulation by the Disease Microenvironment (RTDM)
|
||||
| Disease Class: Colorectal cancer | [1] | |||
| Resistant Disease | Colorectal cancer [ICD-11: 2B91.1] | |||
| Resistant Drug | Doxorubicin | |||
| Molecule Alteration | Expression | Down-regulation |
||
| Experimental Note | Identified from the Human Clinical Data | |||
| Cell Pathway Regulation | Cell migration | Activation | hsa04670 | |
| Cell proliferation | Activation | hsa05200 | ||
| ERK/p38 signaling pathway | Inhibition | hsa04210 | ||
| In Vitro Model | HCT116 cells | Colon | Homo sapiens (Human) | CVCL_0291 |
| HT-29 cells | Colon | Homo sapiens (Human) | CVCL_0320 | |
| Experiment for Molecule Alteration |
RT-qPCR | |||
| Experiment for Drug Resistance |
MTT assay | |||
| Mechanism Description | SLC25A25-AS1 overexpression significantly inhibited proliferation and colony formation in colorectal cancer cell lines, and downregulation of SLC25A25-AS1 obviously (+) chemoresistance and promoted EMT process in vitro associated with Erk and p38 signaling pathway activation. Therefore, SLC25A25-AS1 was determined to play a tumor suppressive role in CRC. | |||
Fluorouracil
| Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
|
Regulation by the Disease Microenvironment (RTDM)
|
||||
| Disease Class: Colorectal cancer | [1] | |||
| Resistant Disease | Colorectal cancer [ICD-11: 2B91.1] | |||
| Resistant Drug | Fluorouracil | |||
| Molecule Alteration | Expression | Down-regulation |
||
| Experimental Note | Identified from the Human Clinical Data | |||
| Cell Pathway Regulation | Cell migration | Activation | hsa04670 | |
| Cell proliferation | Activation | hsa05200 | ||
| ERK/p38 signaling pathway | Inhibition | hsa04210 | ||
| In Vitro Model | HCT116 cells | Colon | Homo sapiens (Human) | CVCL_0291 |
| HT-29 cells | Colon | Homo sapiens (Human) | CVCL_0320 | |
| Experiment for Molecule Alteration |
RT-qPCR | |||
| Experiment for Drug Resistance |
MTT assay | |||
| Mechanism Description | SLC25A25-AS1 overexpression significantly inhibited proliferation and colony formation in colorectal cancer cell lines, and downregulation of SLC25A25-AS1 obviously (+) chemoresistance and promoted EMT process in vitro associated with Erk and p38 signaling pathway activation. Therefore, SLC25A25-AS1 was determined to play a tumor suppressive role in CRC. | |||
Disease- and Tissue-specific Abundances of This Molecule
ICD Disease Classification 02
Colorectal cancer [ICD-11: 2B91]
| Differential expression of molecule in resistant diseases | ||
| The Studied Tissue | Rectum | |
| The Specified Disease | Rectum adenocarcinoma | |
| The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 6.42E-01; Fold-change: -1.90E-02 | |
|
Molecule expression in the diseased tissue of patients
Molecule expression in the normal tissue of healthy individuals
|
||
| Disease-specific Molecule Abundances |
|
Click to View the Clearer Original Diagram |
Tissue-specific Molecule Abundances in Healthy Individuals
|
||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.